

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

Most recent changes to the CPT[®] Category I New Vaccine Codes Long Descriptor document

- Updated effective date for codes 0071A, 0072A and 91307.
- Removal of FDA approval pending symbol (✓) from code 91307.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

The following codes were accepted by the CPT Editorial Panel. Codes 0001A, 0002A, and 91300 are effective December 11, 2020. Codes 0011A, 0012A, and 91301 are effective December 18, 2020. Codes 0031A and 91303 are effective February 27, 2021. Revised code 0031A is effective October 20, 2021. 0003A and 0013A are effective August 12, 2021. Code 0004A is effective on September 22, 2021. Codes 0034A, 0064A, and 91306 are effective October 20, 2021. Codes 0071A, 0072A, and 91307 are effective October 29, 2021.

Codes 0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 91302, 91304, and 91305 will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

*Note codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, and resequenced codes 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, and 0072A will follow code 90474. Resequenced codes 91300, 91301, 91302, 91303, 91304, 91305, 91306, and 91307 will precede code 90476.

Code	Long Code Descriptor	Released to AMA website	Effective	Publication
	<p>Evaluation and Management Preventive Medicine Services</p> <p>► Vaccine/toxoid products, immunization administrations, ancillary studies involving laboratory, radiology, other procedures, or screening tests (eg, vision, hearing, developmental) identified with a specific CPT code are reported separately. For immunization administration and vaccine risk/benefit counseling, see 90460, 90461, 90471-90474, 0001A, 0002A, <u>0003A</u>, <u>0004A</u>, 0011A, 0012A, <u>0013A</u>, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>, <u>0071A</u>, <u>0072A</u>. For vaccine/toxoid products, see 90476-90759, 91300, 91301, 91302, 91303, 91304, <u>91305</u>, <u>91306</u>, <u>91307</u>. ◀</p>	<p>Revised Guidelines Released to AMA Website</p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p>	<p>New and Revised Guidelines Effective</p> <p>0001A, 0002A, 91300: December 11, 2020</p> <p>0011A, 0012A, 91301: December 18, 2020</p> <p>0031A, 91303: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p>0004A: September 22, 2021</p> <p>0034A, 0064A, 91306: October 20, 2021</p> <p><u>0071A, 0072A, 91307: October 29, 2021</u></p> <p>0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 91302, 91304,</p>	<p>New and Revised Guidelines Publication</p> <p>CPT[®] 2022/2023</p>

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

			91305: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	
	<p>Medicine Immunization Administration for Vaccines/Toxoids</p> <p>► Report vaccine immunization administration codes (90460, 90461, 90471-90474, 0001A, 0002A, <u>0003A</u>, <u>0004A</u>, 0011A, 0012A, <u>0013A</u>, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>, <u>0071A</u>, <u>0072A</u>) in addition to the vaccine and toxoid code(s) (90476-90759, 91300, 91301, 91302, 91303, 91304, <u>91305</u>, <u>91306</u>, <u>91307</u>).</p> <p>Report codes 90460 and 90461 only when the physician or other qualified health care professional provides face-to-face counseling of the patient/family during the administration of a vaccine other than when performed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines. For immunization administration of any vaccine, other than SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines, that is not accompanied by face-to-face physician or other qualified health care professional counseling to the patient/family/guardian or for administration of vaccines to patients over 18 years of age, report 90471-90474. (See also Instructions for Use of the CPT Codebook for definition of reporting qualifications.) ◀</p>	<p>New and Revised Guidelines Released to AMA Website</p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p>	<p>New and Revised Guidelines Effective</p> <p>0001A, 0002A, 91300: December 11, 2020</p> <p>0011A, 0012A, 91301: December 18, 2020</p> <p>0031A, 91303: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p>0004A: September 22, 2021</p> <p>0034A, 0064A, 91306: October 20, 2021</p> <p><u>0071A, 0072A, 91307: October 29, 2021</u></p> <p>0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A 91302, 91304, 91305: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p>New and Revised Guidelines Publication</p> <p>CPT[®] 2022/2023</p>
	<p>► Report 0001A, 0002A, 0003A, <u>0004A</u>, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>, <u>0071A</u>, <u>0072A</u> for immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only. Each administration code is specific to each individual vaccine product (eg, 91300, 91301, 91302, 91303, 91304, <u>91305</u>, <u>91306</u>, <u>91307</u>), the</p>	<p>New and Revised Guidelines Released to AMA Website</p> <p>November 10, 2020</p>	<p>New and Revised Guidelines Effective</p>	<p>New and Revised Guidelines Publication</p>

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p>dosage schedule (eg, first dose, second dose), and counseling, when performed. The appropriate administration code is chosen based on the type of vaccine and the specific dose number the patient receives in the schedule. For example, 0012A is reported for the second dose of vaccine 91301. Do not report 90460-90474 for the administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines. Codes related to SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine administration are listed in Appendix Q, with their associated vaccine code descriptors, vaccine administration codes, vaccine manufacturer, vaccine name(s), National Drug Code (NDC) Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q. ◀</p> <p>If a significant separately identifiable Evaluation and Management service (eg, new or established patient office or other outpatient services [99202-99215], office or other outpatient consultations [99241-99245], emergency department services [99281-99285], preventive medicine services [99381-99429]) is performed, the appropriate E/M service code should be reported in addition to the vaccine and toxoid administration codes.</p> <p>A component refers to all antigens in a vaccine that prevent disease(s) caused by one organism (90460 and 90461). Multi-valent antigens or multiple serotypes of antigens against a single organism are considered a single component of vaccines. Combination vaccines are those vaccines that contain multiple vaccine components. Conjugates or adjuvants contained in vaccines are not considered to be component parts of the vaccine as defined above.</p> <p style="padding-left: 40px;">(For allergy testing, see 95004 et seq)</p> <p style="padding-left: 40px;">(For skin testing of bacterial, viral, fungal extracts, see 86485-86580)</p> <p style="padding-left: 40px;">(For therapeutic or diagnostic injections, see 96372-96379)</p>	<p>December 17, 2020</p> <p>January 19, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p>	<p>0001A, 0002A, 91300: December 11, 2020</p> <p>0011A, 0012A, 91301: December 18, 2020</p> <p>0031A, 91303: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p>0004A: September 22, 2021</p> <p>0034A, 0064A, 91306: October 20, 2021</p> <p>0071A, 0072A, 91307: October 29, 2021</p> <p>0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 91302, 91304, 91305: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p>CPT[®] 2022/2023</p>
<p>90460</p>	<p>Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered</p>			
<p>✚90461</p>	<p>each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)</p> <p>(Use 90460 for each vaccine administered. For vaccines with multiple components [combination vaccines], report 90460 in conjunction with 90461 for each additional component in a given vaccine)</p> <p>▶(Do not report 90460, 90461 in conjunction with 91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}]</p>	<p>New Parenthetical Note Released to AMA Website</p> <p>November 10, 2020</p> <p>Revised Parenthetical Note Released to AMA Website</p> <p>December 17, 2020</p>	<p>New and Revised Parenthetical Note Effective</p> <p>91300: December 11, 2020</p> <p>91301: December 18, 2020</p> <p>91303: February 27, 2021</p>	<p>New and Revised Parenthetical Note Publication</p> <p>CPT[®] 2022/2023</p>

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◀	January 19, 2021 March 1, 2021 May 4, 2021 September 3, 2021 October 6, 2021	91306: October 20, 2021 91307: October 29, 2021 91302, 91304, 91305: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) (Do not report 90471 in conjunction with 90473)			
+90472	each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) (Use 90472 in conjunction with 90460, 90471, 90473) ▶(Do not report 90471, 90472 in conjunction with 91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◀ For immune globulins, see 90281-90399. For administration of immune globulins, see 96365, 96366, 96367, 96368, 96369, 96370, 96371, 96374) (For intravesical administration of BCG vaccine, see 51720, 90586)	New Parenthetical Note Released to AMA Website November 10, 2020 Revised Parenthetical Note Released to AMA Website December 17, 2020 January 19, 2021 March 1, 2021 May 4, 2021 September 3, 2021 October 6, 2021	New and Revised Parenthetical Note Effective 91300: December 11, 2020 91301: December 18, 2020 91303: February 27, 2021 91306: October 20, 2021 91307: October 29, 2021 91302, 91304, 91305: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	New and Revised Parenthetical Note Publication CPT [®] 2022/2023
90473	Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid) (Do not report 90473 in conjunction with 90471)			
+90474	each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)		New and Revised Parenthetical Note	New and Revised

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

		New Parenthetical Note Released to AMA Website	Effective	Parenthetical Note Publication
	(Use 90474 in conjunction with 90460, 90471, 90473) ▶(Do not report 90473, 90474 in conjunction with 91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter)◀	November 10, 2020 Revised Parenthetical Note Released to AMA Website December 17, 2020 January 19, 2021 March 1, 2021 May 4, 2021 September 3, 2021 October 6, 2021	91300: December 11, 2020 91301: December 18, 2020 91303: February 27, 2021 91306: October 20, 2021 91307: October 29, 2021 91302, 91304, 91305: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022/2023
●0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose	November 10, 2020	December 11, 2020	CPT [®] 2022
●0002A	second dose	November 10, 2020	December 11, 2020	CPT [®] 2022
●0003A	third dose	July 30, 2021	0003A: August 12, 2021	CPT [®] 2022/2023
●0004A	booster dose ▶(Report 0001A, 0002A, 0003A, 0004A for the administration of vaccine 91300)◀ ▶(Do not report 0001A, 0002A, 0003A, 0004A in conjunction with 91305, 91307)◀	September 3, 2021 October 6, 2021	0001A, 0002A: December 11, 2020 0003A: August 12, 2021 0004A: September 22, 2021 91307: October 29, 2021	CPT [®] 2022/2023

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

#●0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
#●0052A	second dose	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
#●0053A	third dose	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
#●0054A	booster dose ▶(Report 0051A, 0052A, 0053A, 0054A for the administration of vaccine 91305)◀ ▶(Do not report 0051A, 0052A, 0053A, 0054A in conjunction with 91300, 91307)◀	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
#●0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	October 6, 2021	October 29, 2021	CPT [®] 2023
#●0072A	second dose ▶(Report 0071A, 0072A for the administration of vaccine 91307)◀ ▶(Do not report 0071A, 0072A in conjunction with 91300, 91305)◀	October 6, 2021	October 29, 2021	CPT [®] 2023
●0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose	November 10, 2020	December 18, 2020	CPT [®] 2022
●0012A	second dose	November 10, 2020	December 18, 2020	CPT [®] 2022

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

●0013A	<p style="text-align: center;">third dose</p> <p>▶(Report 0011A, 0012A, <u>0013A</u> for the administration of vaccine 91301) ◀</p>	August 16, 2021	<p>0011A, 0012A, 91301: December 18, 2020</p> <p>0013A: August 12, 2021</p>	CPT [®] 2022/2023
#●0064A	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose</p> <p>▶(Report 0064A for the administration of vaccine 91306) ◀</p>	September 3, 2021	October 20, 2021	CPT [®] 2023
●0021A	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10¹⁰ viral particles/0.5 mL dosage; first dose</p>	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
●0022A	<p style="text-align: center;">second dose</p> <p>▶(Report 0021A, 0022A for the administration of vaccine 91302) ◀</p>	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
▲●0031A	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5 mL dosage; single dose</p>	<p style="text-align: center;">New Code Released to AMA Website</p> <p>January 19, 2021</p> <p style="text-align: center;">Revised Code Released to AMA Website</p> <p>October 27, 2021</p>	<p style="text-align: center;">New Code Effective</p> <p>February 27, 2021</p> <p style="text-align: center;">Revised Code Effective</p> <p>October 20, 2021</p>	CPT [®] 2022/2023
●0034A	<p style="text-align: center;">booster dose</p> <p>▶(Report 0031A, <u>0034A</u> for the administration of vaccine 91303) ◀</p>	October 27, 2021	<p>0031A, 91303: February 27, 2021</p> <p>0034A: October 20, 2021</p>	CPT [®] 2023

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

●0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose	May 4, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
●0042A	second dose ▶(Report 0041A, 0042A for the administration of vaccine 91304)◀	May 4, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
	<p>Vaccines, Toxoids</p> <p>To assist users to report the most recent new or revised vaccine product codes, the American Medical Association (AMA) currently uses the CPT website, which features updates of CPT Editorial Panel actions regarding these products. Once approved by the CPT Editorial Panel, these codes will be made available for release on a semiannual (twice a year: July 1 and January 1) basis. As part of the electronic distribution, there is a six-month implementation period from the initial release date (ie, codes released on January 1 are eligible for use on July 1 and codes released on July 1 are eligible for use January 1).</p> <p>The CPT Editorial Panel, in recognition of the public health interest in vaccine products, has chosen to publish new vaccine product codes prior to approval by the US Food and Drug Administration (FDA). These codes are indicated with the <i>ℵ</i> symbol and will be tracked by the AMA to monitor FDA approval status. Once the FDA status changes to approval, the <i>ℵ</i> symbol will be removed. CPT users should refer to the AMA CPT website (www.ama-assn.org/go/cpt-vaccine) for the most up-to-date information on codes with the <i>ℵ</i> symbol.</p>			
	<p>▶ Codes 90476-90759, 91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307 identify the vaccine product only. To report the administration of a vaccine/toxoid other than SARS-CoV-2 (coronavirus disease [COVID-19]), the vaccine/toxoid product codes (90476-90759) must be used in addition to an immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). To report the administration of a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (91300, 91301, 91302, 91303, 91304, <u>91305, 91306, 91307</u>) should be reported with the corresponding immunization administration code (0001A, 0002A, <u>0003A, 0004A</u>, 0011A, 0012A, <u>0013A</u>, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A</u>). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine</p>	<p>New and Revised Guidelines Released to AMA Website</p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p>	<p>New and Revised Guidelines Effective</p> <p>0001A, 0002A, 91300: December 11, 2020</p> <p>0011A, 0012A, 91301: December 18, 2020</p> <p>0031A, 91303: February 27, 2021</p>	<p>New and Revised Guidelines Publication</p> <p style="text-align: center;">CPT[®] 2022/2023</p>

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p>administration codes, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q. ◀</p> <p>▶Do not report 90476-90759 in conjunction with the SARS-CoV-2 (coronavirus disease [COVID-19]) immunization administration codes 0001A, 0002A, <u>0003A</u>, <u>0004A</u>, 0011A, 0012A, <u>0013A</u>, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>, <u>0071A</u>, <u>0072A</u>, unless both a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter. ◀</p> <p>▶Modifier 51 should not be reported with vaccine/toxoid codes 90476-90759, 91300, 91301, 91302, 91303, 91304, <u>91305</u>, <u>91306</u>, <u>91307</u>, when reported in conjunction with administration codes 90460, 90461, 90471, 90472, 90473, 90474, 0001A, 0002A, 0003A, <u>0004A</u>, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>, <u>0071A</u>, <u>0072A</u>. ◀</p> <p>If a significantly separately identifiable Evaluation and Management (E/M) service (eg, office or other outpatient services, preventive medicine services) is performed, the appropriate E/M service code should be reported in addition to the vaccine and toxoid administration codes.</p> <p>To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (eg, Vaccine Adverse Event Reporting System) the exact vaccine product administered needs to be reported. Multiple codes for a particular vaccine are provided in the CPT codebook when the schedule (number of doses or timing) differs for two or more products of the same vaccine type (eg, hepatitis A, Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of administration.</p>	<p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p>	<p>0003A, 0013A: August 12, 2021</p> <p>0004A: September 22, 2021</p> <p>0034A, 0064A, 91306: October 20, 2021</p> <p><u>0071A, 0072A,</u> <u>91307: October 29,</u> <u>2021</u></p> <p>0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 91302, 91304, 91305: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	
	<p>The “when administered to” age descriptions included in CPT vaccine codes are not intended to identify a product’s licensed age indication. The term “preservative free” includes use for vaccines that contain no preservative and vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product’s prescribing information (PI) for the licensed age indication before administering vaccine to a patient.</p> <p>Separate codes are available for combination vaccines (eg, Hib-HepB, DTap-IPV/Hib). It is inappropriate to code each component of a combination vaccine separately. If a specific vaccine code is not available, the unlisted procedure code should be reported, until a new code becomes available.</p>	<p>New and Revised Guidelines Released to AMA Website</p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p>	<p>New and Revised Guidelines Effective</p> <p>91300: December 11, 2020</p> <p>91301: December 18, 2020</p> <p>91303: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p>0004A: September 22, 2021</p>	<p>New and Revised Guidelines Publication</p> <p>CPT[®] 2022/2023</p>

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p>►The vaccine/toxoid abbreviations listed in codes 90476-90759, 91300, 91301, 91302, 91303, 91304, <u>91305, 91306, 91307</u> reflect the most recent US vaccine abbreviations references used in the Advisory Committee on Immunization Practices (ACIP) recommendations at the time of CPT code set publication. Interim updates to vaccine code descriptors will be made following abbreviation approval by the ACIP on a timely basis via the AMA CPT website (www.ama-assn.org/go/cpt-vaccine). The accuracy of the ACIP vaccine abbreviation designations in the CPT code set does not affect the validity of the vaccine code and its reporting function.</p> <p><u>For the purposes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccinations, codes 0003A, 0013A, and 0053A represent the administration of a third dose when the initial immune response following a two-dose primary vaccine series is likely to be insufficient (eg, immunocompromised patient). In contrast, the booster dose codes 0004A, 0034A, 0054A, and 0064A represent the administration of a dose of vaccine when the initial immune response to a primary vaccine series was sufficient, but has likely waned over time.</u> ◀</p> <p>(For immune globulins, see 90281-90399. For administration of immune globulins, see 96365-96375)</p>	October 27, 2021	<p>0034A, 0064A, 91036: October 20, 2021</p> <p><u>91307: October 29, 2021</u></p> <p>0053A, 0054A, 91302, 91304, 91305: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	
#●91300	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use</p> <p>►(Report 91300 with administration codes 0001A, 0002A, <u>0003A, 0004A</u>) ◀</p> <p>►Do not report 91300 in conjunction with administration codes 0051A, 0052A, 0053A, 0054A, <u>0071A, 0072A</u>) ◀</p>	<p>November 10, 2020</p> <p>July 30, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p>	<p>0001A, 0002A, 91300: December 11, 2020</p> <p>0003A: August 12, 2021</p> <p>0004A: September 22, 2021</p> <p><u>0071A, 0072A: October 29, 2021</u></p> <p>0051A, 0052A, 0053A, 0054A: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	CPT [®] 2022/2023

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

#●91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use ▶(Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A)◀ ▶Do not report 91305 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, <u>0071A, 0072A</u>)◀	September 3, 2021 October 6, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
#●91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use ▶(Report 91307 with administration codes 0071A, 0072A)◀ ▶Do not report 91307 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A)◀	October 6, 2021	October 29, 2021	CPT [®] 2023
#●91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use ▶(Report 91301 with administration codes 0011A, 0012A, 0013A)◀	November 10, 2020 August 16, 2021	0011A, 0012A, 91301: December 18, 2020 0013A: August 12, 2021	CPT [®] 2022/2023
#●91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use ▶(Report 91306 with administration code 0064A)◀	September 3, 2021	October 20, 2021	CPT [®] 2023
#●91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use ▶(Report 91302 with administration codes 0021A, 0022A)◀	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
#●91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use ▶(Report 91303 with administration code 0031A, <u>0034A</u>)◀	January 19, 2021 October 27, 2021	0031A, 91303: February 27, 2021 0034A: October 20, 2021	CPT [®] 2022/2023
#●91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine,	May 4, 2021	Effective upon receiving	CPT [®] 2022

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p>recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use</p> <p>►(Report 91304 with administration codes 0041A, 0042A) ◀</p>		Emergency Use Authorization or approval from the Food and Drug Administration	
90476	Adenovirus vaccine, type 4, live, for oral use			
96372	<p>Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration</p> <p>Therapeutic, Prophylactic, and Diagnostic Injections and Infusions (Excludes Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration)</p> <p>Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular</p> <p>►(For administration of vaccines/toxoids, see 90460, 90461, 90471, 90472, 0001A, 0002A, <u>0003A, 0004A</u>, 0011A, 0012A, <u>0013A</u>, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, <u>0072A</u>) ◀</p>	<p>Revised Parenthetical Note Released to AMA Website</p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p>	<p>Revised Parenthetical Note Effective</p> <p>0001A, 0002A: December 11, 2020</p> <p>0011A, 0012A: December 18, 2020</p> <p>0031A: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p>0004A: September 22, 2021</p> <p>0034A, 0064A: October 20, 2021</p> <p>0071A, 0072A: October 29, 2021</p> <p>0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p>Revised Parenthetical Note Publication</p> <p>CPT[®] 2022/2023</p>
	<p>►Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines ◀</p> <p>►This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (91300, 91301, 91302, 91303, 91304, <u>91305, 91306, 91307</u>) to their associated immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A,</p>	<p>New Appendix Q Released to AMA Website</p> <p>November 10, 2020</p> <p>Revised Appendix Q Released to AMA Website</p>	<p>Appendix Q Effective</p> <p>0001A, 0002A, 91300: December 11, 2020</p> <p>0011A, 0012A, 91301: December 18, 2020</p>	<p>Appendix Q Publication</p> <p>CPT[®] 2022/2023</p>

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p>0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>, <u>0071A</u>, <u>0072A</u>), manufacturer name, vaccine name(s), 10- and 11-digit National Drug Code (NDC) Labeler Product ID, and interval between doses. These codes are also located in the Medicine section of the CPT code set. ◀</p> <p>▶Additional introductory and instructional information for codes 0001A, 0002A, <u>0003A</u>, <u>0004A</u>, 0011A, 0012A, <u>0013A</u>, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>, <u>0071A</u>, <u>0072A</u> and 91300, 91301, 91302, 91303, 91304, <u>91305</u>, <u>91306</u>, <u>91307</u> can be found in the Immunization Administration for Vaccines/Toxoids and Vaccines, Toxoids guidelines in the Medicine section of the CPT code set. ◀</p>	<p>December 17, 2020</p> <p>January 19, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p>	<p>0031A, 91303: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p>0004A: September 22, 2021</p> <p>0034A, 0064A, 91306: October 20, 2021</p> <p><u>0071A, 0072A,</u> <u>91307: October 29,</u> <u>2021</u></p> <p>0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 91302, 91304, 91305: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	
--	--	---	--	--

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines					
Vaccine Code	Vaccine Administration Code(s)	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
#●91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	<ul style="list-style-type: none"> ●0001A (1st Dose) ●0002A (2nd Dose) ●0003A (3rd Dose) ●0004A (Booster) 	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine / <u>Comirnaty</u>	59267-1000-1 59267-1000-01	<u>1st Dose to 2nd Dose: 21 Days</u> <u>2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 48-28 or More Days</u> <u>Booster: Refer to FDA/CDC Guidance</u>
#▲●91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	<ul style="list-style-type: none"> #●0051A (1st Dose) #●0052A (2nd Dose) #●0053A (3rd Dose) #●0054A (Booster) 	<u>Pfizer, Inc</u>	<u>Pfizer-BioNTech COVID-19 Vaccine</u>	<u>59267-1025-1</u> <u>59267-1025-01</u>	<u>1st Dose to 2nd Dose: 21 Days</u> <u>2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 28 or More Days</u> <u>Booster: Refer to FDA/CDC Guidance</u>
#▲●91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	<ul style="list-style-type: none"> #●0071A (1st Dose) #●0072A (2nd Dose) 	<u>Pfizer, Inc</u>	<u>Pfizer-BioNTech COVID-19 Vaccine</u>	<u>59267-1055-1</u> <u>59267-1055-01</u>	<u>1st Dose to 2nd Dose: 21 Days</u>
#●91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	<ul style="list-style-type: none"> ●0011A (1st Dose) ●0012A (2nd Dose) ●0013A (3rd Dose) 	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	<u>1st Dose to 2nd Dose: 28 Days</u> <u>2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 28 or More Days</u>

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<p>#●91306 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use</p>	<p>#●0064A (Booster)</p>	<p>Moderna, Inc</p>	<p>Moderna COVID-19 Vaccine</p>	<p>80777-273-10 80777-0273-10</p>	<p><u>Refer to FDA/CDC Guidance</u></p>
<p>#✓●91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10¹⁰ viral particles/0.5 mL dosage, for intramuscular use</p>	<p>●0021A (1st Dose) ●0022A (2nd Dose)</p>	<p>AstraZeneca, Plc</p>	<p>AstraZeneca COVID-19 Vaccine</p>	<p>0310-1222-10 00310-1222-10</p>	<p>28 Days</p>
<p>#●91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5 mL dosage, for intramuscular use</p>	<p>▲●0031A (Single Dose) ●0034A (Booster)</p>	<p>Janssen</p>	<p>Janssen COVID-19 Vaccine</p>	<p>59676-580-05 59676-0580-05</p>	<p>Not Applicable <u>Booster: Refer to FDA/CDC Guidance</u></p>
<p>#✓●91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use</p>	<p>●0041A (1st Dose) ●0042A (2nd Dose)</p>	<p>Novavax, Inc</p>	<p>Novavax COVID-19 Vaccine</p>	<p>80631-100-01 80631-1000-01</p>	<p>21 Days</p>